| Literature DB >> 28628658 |
Cynthia L Bethea1,2,3, Kevin Mueller1, Arubala P Reddy4, Steven G Kohama2, Henryk F Urbanski2,5.
Abstract
The beneficial effects of bioidentical ovarian steroid hormone therapy (HT) during the perimenopause are gaining recognition. However, the positive effects of estrogen (E) plus or minus progesterone (P) administration to ovariectomized (Ovx) lab animals were recognized in multiple systems for years before clinical trials could adequately duplicate the results. Moreover, very large numbers of women are often needed to find statistically significant results in clinical trials of HT; and there are still opposing results being published, especially in neural and cardiovascular systems. One of the obvious differences between human and animal studies is diet. Laboratory animals are fed a diet that is low in fat and refined sugar, but high in micronutrients. In the US, a large portion of the population eats what is known as a "western style diet" or WSD that provides calories from 36% fat, 44% carbohydrates (includes 18.5% sugars) and 18% protein. Unfortunately, obesity and diabetes have reached epidemic proportions and the percentage of obese women in clinical trials may be overlooked. We questioned whether WSD and obesity could decrease the positive neural effects of estradiol (E) in the serotonin system of old macaques that were surgically menopausal. Old ovo-hysterectomized female monkeys were fed WSD for 2.5 years, and treated with placebo, Immediate E (ImE) or Delayed E (DE). Compared to old Ovx macaques on primate chow and treated with placebo or E, the WSD-fed monkeys exhibited greater individual variance and blunted responses to E-treatment in the expression of genes related to serotonin neurotransmission, CRH components in the midbrain, synapse assembly, DNA repair, protein folding, ubiquitylation, transport and neurodegeneration. For many of the genes examined, transcript abundance was lower in WSD-fed than chow-fed monkeys. In summary, an obesogenic diet for 2.5 years in old surgically menopausal macaques blunted or increased variability in E-induced gene expression in the dorsal raphe. These results suggest that with regard to function and viability in the dorsal raphe, HT may not be as beneficial for obese women as normal weight women.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28628658 PMCID: PMC5476244 DOI: 10.1371/journal.pone.0178788
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
ANOVA statistics for all genes.
| Gene Name | 2-way ANOVA on all groups (df = 1,12/effect) | 1-way ANOVA on WSD (df = 2,12) | ||||||
|---|---|---|---|---|---|---|---|---|
| Diet | E treatment | Interaction | ||||||
| F | P | F | P | F | P | F | P | |
| 1.168 | 0.301 | 3.367 | 0.091 | 1.45 | 0.242 | 2.263 | 0.1466 | |
| 7.835 | 0.0161 | 9.66 | 0.0091 | 11.42 | 0.0055 | 1.076 | 0.3718 | |
| 166.7 | <0.0001 | 78.17 | <0.0001 | 77.34 | <0.0001 | 0.2045 | 0.2045 | |
| 22.68 | 0.0005 | 14.51 | 0.0025 | 11.75 | 0.005 | 4.865 | 0.0284 | |
| 10.48 | 0.0071 | 0.4297 | 0.5245 | 0.0012 | 0.0727 | 0.8157 | 0.4654 | |
| 35.81 | <0.0001 | 30.84 | 0.0001 | 10.28 | 0.0075 | 4.252 | 0.0402 | |
| 51.15 | <0.0001 | 26.65 | 0.0002 | 26.52 | 0.0002 | 0.8205 | 0.4635 | |
| 8.183 | 0.0143 | 4.641 | 0.0522 | 2.823 | 0.1187 | 0.2552 | 0.7797 | |
| 7.438 | 0.0184 | 7.222 | 0.0198 | 4.789 | 0.0492 | 1.065 | 0.3751 | |
| 63.53 | <0.0001 | 70.41 | <0.0001 | 59.95 | <0.0001 | 0.9797 | 0.4035 | |
| 29.65 | 0.0001 | 33.08 | <0.0001 | 30.7 | 0.0001 | 0.5291 | 0.6023 | |
| 0.6342 | 0.4382 | 1.932 | 0.1849 | 0.2145 | 0.6499 | 1.329 | 0.3042 | |
| 1.917 | 0.1913 | 10.09 | 0.008 | 4.066 | 0.0667 | 2.079 | 0.1678 | |
| 7.993 | 0.153 | 0.1812 | 0.6779 | 0.1081 | 0.748 | 0.4784 | 0.6321 | |
| 0.2724 | 0.6112 | 3.624 | 0.0812 | 3.321 | 0.934 | 0.3509 | 0.711 | |
| 0.9765 | 0.3426 | 2.778 | 0.1215 | 0.3987 | 0.5396 | 1.236 | 0.325 | |
| 10.57 | 0.0069 | 12.08 | 0.0046 | 15.29 | 0.0021 | 2.737 | 0.1049 | |
| 3.209 | 0.00985 | 12.04 | 0.0046 | 4.879 | 0.0474 | 2.482 | 0.1253 | |
| 48.67 | <0.0001 | 55.4 | <0.0001 | 57.4 | <0.0001 | 0.2362 | 0.7935 | |
| 20.79 | 0.0007 | 10.1 | 0.0079 | 10.35 | 0.0074 | 2.073 | 0.1686 | |
| 0.0986 | 0.7588 | 17.06 | 0.0014 | 1.676 | 0.2198 | 1.703 | 0.2234 | |
| 179.5 | <0.0001 | 70.54 | <0.0001 | 70.53 | <0.0001 | 2.476 | 0.1258 | |
| 25.18 | 0.0003 | 9.899 | 0.0084 | 9.896 | 0.0084 | 0.5156 | 0.6098 | |
| 45.24 | <0.0001 | 15.82 | 0.0018 | 13.39 | 0.0033 | 1.599 | 0.2423 | |
| 8.505 | 0.0129 | 10.45 | 0.0072 | 15.04 | 0.0022 | 1.186 | 0.3387 | |
Characteristics of the old macaques used for raphe gene expression at the end of the study.
| Groups | Surgery | Diet | Age (yrs) | Weight (kg) | Interval to ERT | Length of Treatment | Treatment (n) |
|---|---|---|---|---|---|---|---|
| Average Serum E (pg/ml) | |||||||
| Short Interval to ERT | 2 mo | 48 mo | Placebo (n = 4) | ||||
| <30 | |||||||
| Ovx | Chow | 26.6±1.21 | 7.47±0.25 | ||||
| ERT (n = 3) | |||||||
| 94.3±20.5 | |||||||
| No Interval to ERT | OvH | WSD | 0 days | 30 mo | Placebo (n = 5) 6.60 ± 0.16 | ||
| 21.29 ± 0.32 | 8.99 ± 0.31 | ||||||
| 0 days | 30 mo | ImE (n = 6) 82.05 ± 0.93 | |||||
| Long Interval to ERT | OvH | WSD | 2.0 yrs | 6 mo | DE (n = 6) | ||
| 90.78 ± 1.29 | |||||||
*ANOVA p < 0.001
** t-test p<0.001
Available information about the ABI flourescent primers used in this study.
| Gene Name | Gene Symbol | Assay ID | NCBI Gene Reference |
|---|---|---|---|
| Fifth Ewing variant (PET1 in rodent) | Rh02872593 | XM_001095962.2 | |
| Tryptophan hydroxylase 2 | Rh02788839 | NM_001039946.1 | |
| Serotonin reuptake transporter | Rh02787892 | NM_001032823.1 | |
| Serotonin receptor 1A | Rh02902683 | NM_001198700.1 | |
| Corticotropin releasing hormone receptor type 1 | Rh02787591 | NM_001032803.1 | |
| Corticotropin releasing hormone receptor type 2 | Rh01120857 | XM_001085987.2 | |
| Urocortin 1 (stresscopin) | Rh03986716 | NM_001265661.1 | |
| Neuroligin 3 | Rh03986723 | XM_001111843.1 | |
| Neurotrophic tyrosine kinase, receptor, type 2, | Rh02831788 | NM_001261297.1 | |
| Nibrin, part of double strand break repair complex | Rh01039845 | XM_001085033.1 | |
| Nth endonuclease III-like 1, DNA N-glycosylase | Rh00959765 | XM_001082772.2 | |
| Ligase IV, DNA double strand break repair | Rh04269856 | XM_001084107 | |
| RAD23 homolog A, involved in nucleotide excision repair(NER) | Rh00908422 | XM_001110103.2 | |
| Apurinic/apyrimidinic endonuclease 1 | Rh02793202 | XM_001090240.2 | |
| Proliferating cell nuclear antigen, BER gap filling | Rh02806147 | XM_001115746.2 | |
| Heat shock protein 90kD | Rh02790147 | ||
| Heat shock protein 60kD protein1 | Hs01036753 | ||
| Heat shock protein 27kD protein 1 | Rh02980144 | XM_001109274.2 | |
| Ubiquitin-like modifier activating enzyme 1 | Hs01566989 | NM_024818.3 | |
| Ubiquitin-conjugating enzyme E2D 3 | Hs01518517 | NM_181892.2 | |
| Ubiquitin protein ligase E3A | Rh00963674 | XM_002804686.1 | |
| Kinesin family member 5B | Rh01037194 | XM_002805607.1 | |
| Dynein, light chain, LC8-type 1 | Hs00867659 | NM_001037495.1 | |
| Microtubule-associated protein tau | Rh04269822 | XM_001115803.2 | |
| α-secretase cleavage of APP precludes amyloid-β formation | Rh01109565 | XM_001097016.2 | |
| α-synuclein, presynaptic signaling, membrane trafficking | Rh1103386 | ||
| Presenilin (γ-secretase component) produces amyloid-β 40–42 | Rh02826228 | XM_001088635.2 |